Sabinsa has been granted U.S. patent US10166261 for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore^®) at a dose of 2 billion colony forming units per day. The patent also claims LactoSpore’s ability to reduce serum myeloperoxidase, an essential biochemical marker of MDD.

Read more ...

Reduction of TMAO Formation Found, Novel Findings for Heart Health

A new study collaboratively published by Sabinsa researchers and academic scientists from Taiwan and China, demonstrates that Sabinsa’s sustainably-sourced pterostilbene attenuates Trimethylamine-N-oxide (TMAO) formation and decreases vascular inflammation, confirming cardioprotective properties. The animal study findings were published online in the article Prevention of Vascular Inflammation by Pterostilbene via Trimethylamine-N-Oxide Reduction and Mechanism of Microbiota Regulation in Molecular Nutrition and Food Research (Volume 63, Issue 20).

Read more ...

Award Presented During the Economic Times Business Leaders 2019 Award Ceremony

Sabinsa’s parent company Sami Labs Limited received The Economic Times’ Business Leaders 2019 Award for Most Trusted Nutraceutical Company in a ceremony held in Mumbai, India last month. The Economic Times, is the leading financial daily in India and among the world’s top three daily newspapers.

Read more ...

The Sami-Sabinsa Group’s export success was recently recognized by the Visveshwaraiah Trade Promotion Centre (VTPC), under the auspices of the Industries Department, Government of Karnataka, India. Sabinsa’s parent company Sami Labs Limited received three Export Excellence Awards for the financial year 2016-17.

Read more ...

Sabinsa’s Curcumin C3 Complex^®, the #1 researched curcumin ingredient on the market, was used in a new published study on Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver condition for which no approved pharmaceutical treatments exist.

Read more ...

The Sami-Sabinsa Group was honored with numerous awards in recent weeks, being named “best of” in categories ranging from herbal research to beverage taste. The Sami-Sabinsa Group’s founder, Chairman, and Managing Director, Dr. Muhammed Majeed, was commended as well.

Read more ...

Sabinsa’s founder, Chairman, and Managing Director Dr. Muhammed Majeed announced the publication of a new book; this latest is entitled “Reductive Metabolites of Curcuminoids.” Over the last two decades curcuminoids have been the most intensively studied herbal constituents, and Sabinsa has been at the forefront of much of the research.

Read more ...

Sabinsa is the official Curcumin Sponsor of SupplySide West, to be held October 17 - 18, 2019, at the Mandalay Bay Convention Center, Las Vegas, NV. The company will highlight several condition-specific branded ingredient products from its extensive portfolio in booth #4131.

Read more ...

The body of research supporting efficacy of Sabinsa’s branded ingredients continues to grow with a recent clinical paper reporting on the use of the company’s Curcumin C3 Complex^® and BioPerine^®, and taurine on hepatocellular carcinoma (HCC) patients: A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study published in the Journal of Gastrointestional Oncology.

Read more ...

Sabinsa’s Curcumin C3 Complex^® in combination with BioPerine^® (CBP) has an inhibitory effect on malignant mesothelioma cells, according to an in vitro and in vivo study published in Journal of Experimental and Clinical Cancer Research.

Read more ...